Cladribine (2-CdA)
Purine nucleoside analog — cytoreductive chemotherapy
- Response rate
- 50-60% in advanced SM
- Onset
- Weeks–months
- Route
- IV 5mg/m2 daily x5 days, every 4-8 weeks
- Line
- 2nd
- IgM effect
- N/A
Evidence summary
Cytoreductive purine analog with significant activity against monocytic lineage cells that share a common progenitor with mast cells. Used in advanced SM when KIT inhibitors are insufficient. Major limitations include myelosuppression and immunosuppression. May be combined with other agents.